Amgen Aktie - AMGN

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

299,90

( 1,14% )

Gebot

299,76

Fragen

299,97

Volumen

870.785

295,165 Tagesbereich 302,38

253,30 52-Wochen-Bereich 346,85

Marktkapitalisierung

161,258B

Handelsende

296,52

Handelsbeginn

296,19

Letzte Trade

299.87

Letzter Handelszeitpunkt

20:00:36

Finanzvolumen

US$ 260.192.091

VWAP

298,8018

Durchschnittliches Volumen (3 Mio.)

2.839.808

Ausgegebene Aktien

537.706.118

Dividendenrendite

3.17%

Kurs-Gewinn-Verhältnis

39,37

Gewinn pro Aktie (EPS)

7,61

Erlöse

33,42B

Nettogewinn

4,09B

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory disease... Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira). Mehr anzeigen

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.amgen.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Amgen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AMGN. The last closing price for Amgen was US$296,52. Over the last year, Amgen shares have traded in a share price range of US$ 253,30 to US$ 346,85.

Amgen currently has 537.706.118 shares in issue. The market capitalisation of Amgen is US$159,44 billion. Amgen has a price to earnings ratio (PE ratio) of 39.37.

Gesamtfluss

Bärisch

Nettoprämie

-64k

Calls / Puts

100,00%

Käuf. / Verkä.

200,00%

OTM / ITM

166,67%

Sweeps

0,00%

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b...

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	2.9	0.976430976431	297	302.38	291.2514	1783241	295.99747047	CS
4	5.69	1.93399272628	294.21	302.38	267.83	2870723	286.48476878	CS
12	23.43	8.47469888234	276.47	302.38	261.43	2839808	280.80433777	CS
26	37.18	14.1519488429	262.72	335.88	260.55	3057514	290.46876025	CS
52	-17.16	-5.41222481549	317.06	346.85	253.3	2853235	295.32716319	CS
156	50.62	20.3064826701	249.28	346.85	211.73	2676124	274.66990397	CS
260	49.25	19.6489128267	250.65	346.85	198.64	2711019	258.22095417	CS

AMGN - Frequently Asked Questions (FAQ)

What is the current Amgen share price?

The current share price of Amgen is US$ 299,90

How many Amgen shares are in issue?

Amgen has 537.706.118 shares in issue

What is the market cap of Amgen?

The market capitalisation of Amgen is USD 159,44B

What is the 1 year trading range for Amgen share price?

Amgen has traded in the range of US$ 253,30 to US$ 346,85 during the past year

What is the PE ratio of Amgen?

The price to earnings ratio of Amgen is 39,37

What is the cash to sales ratio of Amgen?

The cash to sales ratio of Amgen is 4,82

What is the reporting currency for Amgen?

Amgen reports financial results in USD

What is the latest annual turnover for Amgen?

The latest annual turnover of Amgen is USD 33,42B

What is the latest annual profit for Amgen?

The latest annual profit of Amgen is USD 4,09B

What is the registered address of Amgen?

The registered address for Amgen is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Amgen website address?

The website address for Amgen is www.amgen.com

Which industry sector does Amgen operate in?

Amgen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ABVEAbove Food Ingredients Inc	US$ 1,478 (304,93%)	351,53M
DALNDallasNews Corporation	US$ 13,559 (208,86%)	4,23M
STKHSteakholder Foods Ltd	US$ 3,05 (74,29%)	52,48M
MTENMingteng International Corporation Inc	US$ 18,60 (70,49%)	443,11k
QTTBQ32 Bio Inc	US$ 2,355 (55,96%)	42,57M
CIGLConcorde International Group Ltd	US$ 2,39 (-91,52%)	2,33M
MREOMereo BioPharma Group PLC	US$ 1,747 (-40,58%)	24,5M
CURRCurrenc Group Inc	US$ 1,30 (-35,96%)	2,64M
RAREUltragenyx Pharmaceutical Inc	US$ 29,965 (-27,69%)	9,77M
WHLRLWheeler Real Estate Investment Trust Inc	US$ 113,65 (-24,98%)	33
GIBOGIBO Holdings Ltd	US$ 0,0517 (52,96%)	977,66M
NCNANuCana PLC	US$ 0,0575 (-4,64%)	512,79M
HCTIHealthcare Triangle Inc	US$ 0,02365 (18,25%)	426,64M
ABVEAbove Food Ingredients Inc	US$ 1,478 (304,93%)	351,53M
CGTXCognition Therapeutics Inc	US$ 0,6993 (31,37%)	235,55M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Amgen Inc (AMGN) Börsenkurse

Amgen Inc (AMGN)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Amgen Inc

Option-Flow Amgen (AMGN)

Gesamtfluss

Bärisch

Nettoprämie

-64k

Calls / Puts

100,00%

Käuf. / Verkä.

200,00%

OTM / ITM

166,67%

Sweeps

0,00%

AMGN Neueste Nachrichten

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 4 - Statement of changes in beneficial ownership of securities

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Form 144 - Report of proposed sale of securities

IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

AMGEN AND FOOTBALL LEGEND BARRY SANDERS HIGHLIGHT DANGERS OF BAD CHOLESTEROL IN NEW DOCUMENTARY

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 4 - Statement of changes in beneficial ownership of securities

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

AMGN - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Anmelden

Werbung entfernen